Following Royalty Pharma plc's (NASDAQ: RPRX ) Investor Day (Fig. 1), we are returning with an update in light of the company's supportive Q3 results and its latest investment. Here at the Lab, we reiterate a Buy rating onBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must ...